Lisinopril is under clinical development by Transparency Life Sciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Lisinopril’s likelihood of approval (LoA) and phase transition for Relapsing Remitting Multiple Sclerosis (RRMS) took place on 25 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lisinopril Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Lisinopril is under development as an adjunctive therapy for the treatment of relapsing remitting multiple sclerosis. It is developed as repurposed drug candidate acts by targeting angiotensin converting enzyme.
Transparency Life Sciences overview
Transparency Life Sciences (TLS) is a clinical research technology company to improve human health by including patients in trial design, offering convenient access to trials, generating more relevant and informative data, and reducing the costs of drug development. Transparency Life Sciences is headquartered in New York, New York, the US.
Quick View Lisinopril LOA Data
|Highest Development Stage|